Clinical Trial: SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance

U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07503717) titled 'SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance' on Feb. 16.

Brief Summary: SURVEY-CNS is a feasibility study evaluating whether women and men with HER2-positive metastatic breast cancer can be successfully recruited and randomised to a strategy of central nervous system (CNS) magnetic resonance imaging (MRI) surveillance versus standard of care (no routine CNS surveillance).

Patients with HER2-positive metastatic breast cancer have a high risk of developing brain metastases. Brain metastases can cause significant ...